newsfilter
← Latest News
Business Wire·

HeartBeam Announces Strategic Shift to Accelerate Global Adoption of its Ambulatory ECG Signal Platform and Leadership Transition

  • HeartBeam, Inc. announced a reorganization to prioritize global market reach, capital efficiency, and a leaner operational structure.
  • The company will license its 3D ECG signal technology to established partners rather than relying solely on direct medical device sales.
  • Operations are now aligned around focused implementation teams led by President Branislav Vajdic, Ph.D. & Executive Chairman Rich Ferrari.
  • Former CEO Robert Eno transitioned to a consulting role following the restructuring.
  • A key strategic focus is advancing the platform from arrhythmia assessment to reliable heart attack detection.
  • The company aims to expand its AI-ready 3D signal platform to serve third-party AI applications across the medical field.
  • HeartBeam plans to adapt its technology for five distribution channels: governments, ECG OEMs, Holter/patch manufacturers, health systems, & consumer wearables.
  • FDA marketing clearance for the synthesized 12-lead ECG signal for arrhythmia assessment was received in December 2025.
  • Heart attack detection indications & algorithms are not yet FDA cleared & are not available in the US or other geographies.
  • The company will provide further strategic details during its Second Quarter 2026 conference call scheduled for August.